Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new targeted therapy just got the FDA's stamp of approval for a rare but debilitating joint tumor. Pimicotinib (Pimjetmi) is now approved for symptomatic tenosynovial giant cell tumor (TGCT) in patients where surgery could worsen function or cause serious harm. The approval is backed by phase 3 MANEUVER trial data showing a 76.2% overall response rate — a meaningful win for a condition with historically limited options.
The FDA has approved pimicotinib (Pimjetmi) for adults with symptomatic tenosynovial giant cell tumor (TGCT) — a rare, locally aggressive tumor of the joints — specifically for patients where surgery could worsen functional limitations or cause severe harm. The decision marks another step forward in shifting TGCT management away from the operating room and toward targeted systemic therapy.
The approval is based on data from the phase 3 MANEUVER trial, which showed impressive response rates for pimicotinib, a highly selective CSF-1R inhibitor. Experts say the drug's specificity may offer a better therapeutic profile compared to earlier agents like pexidartinib and vimseltinib. Leading oncologists are increasingly moving away from upfront surgery for diffuse TGCT, reserving it mainly for nodular or less complex cases.
By the Numbers:
Why it matters: For patients with TGCT who face high surgical risk, pimicotinib offers a meaningful alternative — one that could reduce disease burden, preserve function, and in some cases, help patients avoid surgery altogether.
